Onconetix, Inc. (NASDAQ:ONCO) Stock Short Interest Report for October

Onconetix, Inc. (NASDAQ:ONCO) was the target of a significant growth in short interest in October. As of October 30th, there was short interest totaling 957,609 shares, a growth of 145.6% from the October 15th total of 389,871 shares. Based on an average trading volume of 5,373,971 shares, the days-to-cover ratio is currently 0.2 days. Currently, 163.1% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

ONCO has been the subject of a number of recent research reports. Weiss Ratings upgraded Onconetix from a “sell (e)” rating to a “sell (e+)” rating in a research report on Thursday, October 29th. Wall Street Zen raised shares of Onconetix from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Onconetix Stock Performance

NASDAQ ONCO traded up $0.04 during mid-day trading on Friday, reaching $3.08. 29,140 shares of the stock were exchanged, compared to its average volume of 168,222. Onconetix has a 1-year low of $2.91 and a 1-year high of $1,610.00. The business’s fifty day simple moving average is $6.32 and its 200 day simple moving average is $113.93. The stock has a market capitalization of $1.81 million, a PE ratio of 0.00 and a beta of 2.62.

Onconetix (NASDAQ:ONCO) last released its earnings results on Thursday, August 13th. The company reported ($12.80) EPS for the quarter, topping the consensus estimate of ($45,050.00) by $45,037.20. Onconetix had a negative net margin of 1,575.89% and a negative return on equity of 91.95%. The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.02 million.

Onconetix Company Profile

Onconetix, Inc. is a biotechnology company focused on developing and commercializing diagnostic and therapeutic products for men’s health. The company’s portfolio is centered primarily on prostate health, with products intended to support the detection, risk assessment and treatment of prostate-related conditions. Its lead diagnostic product is Proclarix, a blood-based test designed to help assess the risk of clinically significant prostate cancer in men with elevated prostate-specific antigen (PSA) levels.